Eisai and Sato Partner on Fosravuconazole Antifungal in Asia-Pacific

Eisai and Japan's Sato Pharmaceutical have announced a significant partnership through a licensing agreement concerning the development and marketing of the novel antifungal drug Fosravuconazole (Fluxacom) in Asia and Oceania.

As stipulated in the agreement, Eisai grants Sato Pharmaceutical exclusive licensing rights to the intellectual property for Fosravuconazole in the Asia and Oceania regions. This novel antifungal drug, created by Eisai's research and development team, contains the active ingredient ravuconazole. The innovative design of this prodrug enhances its solubility and significantly boosts its bioavailability.

Sato Pharmaceutical first introduced Fosravuconazole to the Japanese market in 2018 under the brand name Nailin®, targeting onychomycosis, including nail fungal infections. This new collaboration is anticipated to speed up the development and commercialization of this innovative drug across the broader Asia-Pacific region.

Under the agreement, Eisai will benefit financially through contract advances, sales milestone payments, and royalties. Moreover, Eisai retains the rights to develop and market medications for tinea pedis and other related conditions.

Eisai aims to maximize Fosravuconazole's market potential in Asia and Oceania through this partnership. The company also hopes for the drug's swift clinical application to offer a new treatment regimen for patients suffering from fungal infections. Both Eisai and Sato Pharmaceutical are committed to jointly promoting the development and application of this innovative therapy, with the goal of providing safer and more effective treatment options. This collaboration is expected to enhance the health and quality of life for many patients.